{"entity":{"id":"amsterdam-umc","kind":"institution","name":"Amsterdam UMC / Cancer Center Amsterdam","aka":["AMC","VUmc","Cancer Center Amsterdam"],"tldr":"The merged Amsterdam university hospitals (AMC and VUmc), whose Cancer Center Amsterdam is one of the largest academic cancer research programmes in the Netherlands.","summary":"Amsterdam UMC was formed by the 2018 merger of the Academic Medical Center (University of Amsterdam) and VU University Medical Center (Vrije Universiteit). Cancer Center Amsterdam is its research and care institute for oncology, spanning medical oncology, haematology, radiotherapy, surgical oncology and imaging on two campuses. Strengths include pancreatic and hepatobiliary surgery, colorectal cancer biology and organoids, lymphoma and leukaemia, imaging and radiotherapy, and cancer immunology, and the centre works alongside the Netherlands Cancer Institute within the Amsterdam cancer ecosystem.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.amsterdamumc.org"}],"tags":[],"related":[],"cancers":["pancreatic","colorectal"],"sections":[],"technologies":["mr-linac"],"targets":[],"drugs":[],"companies":[],"institutions":["nki"],"pathways":[],"terms":[],"trials":[],"people":["hans-van-goudoever"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Amsterdam","country":"NL","lat":52.335,"lng":4.958,"institutionType":"hospital","website":"https://www.amsterdamumc.org","university":"University of Amsterdam / Vrije Universiteit Amsterdam","programs":["Pancreatic and hepatobiliary surgery","Colorectal cancer biology","Haematology","Imaging and radiotherapy"]},"route":"/institutions/amsterdam-umc/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"mr-linac","kind":"technology","name":"MR-guided adaptive radiotherapy","route":"/technologies/mr-linac/"}],"institution":[{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","route":"/institutions/nki/"}],"person":[{"id":"hans-van-goudoever","kind":"person","name":"Hans van Goudoever","route":"/people/hans-van-goudoever/"},{"id":"marc-besselink","kind":"person","name":"Marc G. Besselink","route":"/people/marc-besselink/"}],"paper":[{"id":"paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025","kind":"paper","name":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial","route":"/key-papers/paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025/"},{"id":"paper-preopanc-preoperative-chemoradiotherapy-jco-2020","kind":"paper","name":"Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial","route":"/key-papers/paper-preopanc-preoperative-chemoradiotherapy-jco-2020/"}],"trial":[{"id":"colopec","kind":"trial","name":"COLOPEC","route":"/trials/colopec/"}],"company":[{"id":"dpcg","kind":"company","name":"Dutch Pancreatic Cancer Group","route":"/companies/dpcg/"},{"id":"viewray","kind":"company","name":"ViewRay (MRIdian)","route":"/companies/viewray/"}]}}